| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911252 | Lung Cancer | 2012 | 7 Pages |
Abstract
We conclude that clinical trial data indicate that anti-VEGF therapy can be considered for NSCLC patients with emerging or pretreated CNS metastases.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Alan Sandler, Vera Hirsh, Martin Reck, Joachim von Pawel, Wallace Akerley, David H. Johnson,